151results about "Nuclear receptor" patented technology

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screetng assays, functional genomics and regulation of traits in transgenic plants and animals.

The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain.

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

Disclosed are methods and compositions comprising native, site-specifically mutagenized, and synthetic peptides comprising portions of the human estrogen receptor, or estrogen receptor co-activator, and nucleic acid compositions encoding these polypeptide compositions. Also disclosed are methods for synthesizing phosphotyrosyl and malonyltyrosyl peptide derivatives and their use as antiestrogen compositions in the treatment of breast cancers, the preparation of pharmaceutical compositions, diagnostic kits, and the development of related assays for use in antitumor therapies.

The invention relates to novel mammalian perixosome proliferator-activated receptor (PPAR) poplypeptides and their use. In a particular embodiment, PPAR polypeptides with mutations in the P-box domain possess advantageous properties as transcriptional activators for PPRE-bearing expression vectors and expression systems. The invention includes PPAR polypeptides, nucleic acids encoding them, expression systems, vectors, and methods for inducibly expressing a gene of interest. The methods and expression systems of the invetion provide improved dose-response or inducibility characteristics, improved and/or altered effects on cellular PPAR function, and/or improved transcriptional control. The selection of a homologous PPAR polypeptide to prepare the novel PPAR polypeptide of the invetion for a cell or tissue also improves the immune reaction side effect potential for particular uses.

The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

Disclosed herein are systems, methods and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand.

The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor/transcription factor-regulated genes. Methods for modulating the function of PPAR-γ as well as PPAR-γ-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.

A method for activating an efferent sympathetic nerve innervating an adipose tissue and improving obesity-associated symptoms is provided, comprising stimulating an afferent vagal nerve from the liver without directly enhancing peroxisome proliferator-activated receptor (PPAR)-γ2 function in the liver.

Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.

A therapeutic effect of Nurr1 and Foxa2 in inflammatory neurologic disorders by M1-to-M2 polarization of glial cells is provided. Specifically, a method of converting glial cells from an M1 phenotype to an M2 phenotype, wherein Nurr1 and Foxa2 are introduced into the glial cells to be overexpressed in the glial cells and a method of preventing or treating an inflammatory neurologic disorder, which includes glial cells into which Nurr1 and Foxa2 are introduced, or a viral vector loaded with Nurr1 and Foxa2, are provided.

An EcR-based gene expression modulation system for use in plants includes an EcR gene expression cassette, a modified RXR gene expression cassette, and a gene-of-interest expression cassette, which can be expressed in a host plant cell.

The present invention involves the use of peptides from Notch3, and antibodies that recognize epitopes represented by those peptides, as anti-cancer agents. Methods of combination therapy using standard anti-cancer protocols in conjunction with Notch3 peptides and antibodies also are provided.

The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces.

The invention relates to fusion proteins and bacteria encoding them. The fusion proteins include a ligand-binding domain interposed between the splicing domains of an intein. An auxotroph-relieving protein domain is fused to one of the splicing domains so that the auxotroph-relieving function of the domain is activated upon ligand binding. The fusion proteins can be expressed in bacterial cells and used as sensors of binding of compounds with the ligand-binding domain of proteins such as the human estrogen receptors or the human thyroid hormone receptor. The bacterially expressed fusion proteins can detect and report agonist and antagonist activity characteristic of the naturally-occurring hormone with the ability to modulate the function of the protein from which the ligand-binding domain of the fusion protein is derived.

The invention relates to a compound I and a compound II as well as preparation methods and application thereof. The newly synthesized compound shown in the formula I can stimulate anti-tumor congenital immunity and cellular immunity while greatly improving the anti-tumor effect of ethacrynic acid (EA) and drug design of anti-tumor immunity synergetic integration is explored; the anti-melanoma immune response mechanism of the compound shown in the formula I is proved; the compound shown in the formula II and prepared through covalence of the compound shown in the formula I and ROR1 obviously reduces growth of breast cancer subcutaneously transplanted tumors, the breast cancer treatment immune response mechanism of the compound shown in the formula II is proved, and meanwhile, the fact that the compound shown in the formula I not only has the functions of stimulating congenital immunity and adaptive immunity, but also has the effect of immune adjuvant is proved.

The present invention describes genomic biomarkers that have been discovered to correlate with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic retinoid X receptor modulator, such as bexarotene, in treating diseases such as, non small cell lung cancer. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might have adverse effects, by the treatment.

The invention discloses an endocrine disrupter high-throughput screening model and screening method, and relates to the field of virtual screening and activity prediction of endocrine disrupters. Themethod comprises the following steps: extracting a first-stage warning structure, a second-stage warning structure and a third-stage warning structure of a compound aiming at a nuclear receptor, forming a nuclear receptor high-throughput screening model by the first-stage warning structure, the second-stage warning structure and the third-stage warning structure; carrying out graded warning structure matching on the target compound through a nuclear receptor high-throughput screening model, and carrying out ligand-ligand matching; Analyzing a receptor binding mode; and semi-quantitatively predicting the binding activity and the interference activity. The method overcomes the defect that the potential nuclear receptor-mediated endocrine disrupter cannot be effectively screened in a high throughput manner in the prior art, can be used for screening the potential nuclear receptor-mediated endocrine disrupter in a high throughput manner, and can be used for judging the receptor competitionactivity and the quasi-antibody activity of the nuclear receptor-mediated endocrine disrupter.